PRNewsWire
12 Aug 2026, 10:50 UTC · 11w ago
Impact · against what's priced in
Protalix demonstrates strong commercial execution with a 107% year-over-year revenue increase and a clean balance sheet. While the reaffirmation of guidance is expected, the scale of revenue growth from Elfabrio supports a positive valuation trajectory.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Protalix reported a significant increase in total revenue to $53.6 million for Q2 2026, up from $25.8 million in the same period of 2025.
So whatA more than 100% year-over-year revenue increase demonstrates strong commercial scaling and execution, which is a primary driver for biotech valuations.
More positive than 99% of claims this week
The company reaffirmed its previously stated 2026 revenue expectations.
So whatReaffirming guidance provides market stability and suggests that the company's growth trajectory is predictable and on track.
Continue reading
5 related stories
Total revenue grew significantly to $53.6 million from $25.8 million in Q2 2025, driven by Elfabrio penetration. The company's cash position of $40.7 million and absence of debt reduce near-term financing risks.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 76% of claims this week
Protalix maintains a balance sheet with $40.7 million in cash and short-term deposits and no outstanding debt or warrants.
So whatLack of debt and a clean capital structure reduce the risk of dilutive financing rounds in the near term.
More positive than 62% of claims this week
Enrollment continues for the PRX-115 Phase 2 RELEASE clinical trial for uncontrolled gout.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company reported significant revenue growth to $53.6 million and reaffirmed its positive financial outlook for 2026.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
2h ago
+6.6%
Price agrees with the score
$2.59 vs $2.43 close before publication (Aug 11) · not market-adjusted
PLX chart →
